Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Sonoma Pharmaceuticals Inc. (SNOA:NASDAQ), powered by AI.
Sonoma Pharmaceuticals Inc. is currently trading at $1.14. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Sonoma Pharmaceuticals Inc. on Alpha Lenz.
Sonoma Pharmaceuticals Inc.'s P/E ratio is -0.4.
“Sonoma Pharmaceuticals Inc. trades at a P/E of -0.4 (undervalued) with modest ROE of -65.5%.”
Ask for details →Sonoma Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing healing solutions for dermatological conditions and advanced wound care. The primary purpose of this entity is to create non-toxic therapies that safely reduce infections and inflammation, accelerating the body's natural healing processes. Its product portfolio includes a range of topical anti-infective treatments and skin care solutions tailored for various fields, including dermatology, wound care, eye care, and animal health. Sonoma's formulations commonly feature hypochlorous acid, an element known for its antimicrobial and soothing properties. Significantly impacting the healthcare and pharmaceutical sectors, Sonoma Pharmaceuticals addresses critical needs in infection management and chronic wound therapy. The company’s innovations are particularly beneficial in hospital settings, outpatient clinics, and home care, offering versatile treatment options for both human and animal patients. Headquartered in Boulder, Colorado, the company's reach extends internationally, underscoring its role as a key player in improving patient outcomes through scientifically-backed therapeutic products.
“Sonoma Pharmaceuticals Inc. trades at a P/E of -0.4 (undervalued) with modest ROE of -65.5%.”
Ask for details →Sonoma Pharmaceuticals Inc. (ticker: SNOA) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 8 employees. Market cap is $1M.
The current price is $1.14 with a P/E ratio of -0.41x and P/B of 0.32x.
ROE is -65.55% and operating margin is -25.97%. Annual revenue is $14M.